drugset / Trial / NCT00224042
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
RandomizedParallel-groupOpen-labelTreatment
Summary
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®.
Timeline
- Start
- 2003-04
- Primary completion
- 2005-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 325 mg | Oral |
| Subject | Sodium Ferric Gluconate Complex | Unknown | 250 mg | Intravenous |